OXFORD, England and GERMANTOWN, Md., Jan. 19, 2016 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its subsidiary Oxitec and Piracicaba City Hall have expanded the 'Friendly Aedes aegypti Project' in Piracicaba, Brazil following strong results for controlling the Ae. aegypti mosquito population, the primary vector for dengue, chikungunya and Zika virus outbreaks around the world. In preparation of this growing program and to meet increasing demand for its proprietary vector control solution, Oxitec is initiating a new mosquito production facility in Piracicaba that will have capacity to protect over 300,000 people.
"We are delighted Piracicaba is encouraged by our strong results and expanding the program. Our new facility will support the roll out of our groundbreaking vector-control across the heart of the city and beyond," said Oxitec CEO Hadyn Parry. "As the principal source for the fastest growing vector-borne infection in the world in Dengue Fever, as well as the increasingly challenging Zika virus, controlling the Aedes aegypti population provides the best defense against these serious diseases for which there are no cures."
Following approval by Brazil's National Biosafety Committee (CTNBio) for releases throughout the country, Piracicaba's CECAP/Eldorado district became the world's first municipality to partner directly with Oxitec and in April 2015 started releasing its self-limiting mosquitoes whose offspring do not survive. By the end of the calendar year, results had already indicated a reduction in wild mosquito larvae by 82%. Oxitec's efficacy trials across Brazil, Panama and the Cayman Islands all resulted in a greater than 90% suppression of the wild Ae. aegypti mosquito population – an unprecedented level of control.
Based on the positive results achieved to date, the 'Friendly Aedes aegypti Project' in CECAP/Eldorado district covering 5,000 people has been extended for another year. Additionally Oxitec and Piracicaba have signed a letter of intent to expand the project to an area of 35,000-60,000 residents. This geographic region includes the city's center and was chosen due to the large flow of people commuting between it and surrounding neighborhoods which may contribute to the spread of infestations and infections.
According to Mayor Gabriel Ferrato, "The city of Piracicaba has always sought innovative solutions to serious problems. In the case of Aedes aegypti, we looked for the tool that seemed most appropriate to help in the tough battle against this mosquito that transmits dengue, Zika and chikungunya. Based on the results presented today, we decided to extend the project in CECAP/Eldorado district for another year and also signed a record of intent to expand the project to the central area of Piracicaba. This will bring to the city a new Oxitec factory to meet demand for years to come and help protect the public's health with this clean and innovative technology."
Like many invasive insect species, Ae. aegypti's territory is expanding as are the diseases it spreads, including dengue, chikungunya and Zika virus, which collectively impact over 100 countries and approximately 400 million people globally each year. Today Brazil has the highest reported incidence of dengue in the Western Hemisphere, and with both chikungunya and Zika virus having entered the country in 2014 and 2015 respectively, the Ae. aegypti mosquito has become an increasing health risk. As a result, Brazil's Ministry of Health spent over 1.2 billion reals last year and allocated an additional 500 million reals for states and municipalities in January 2016 to combat the mosquito.
As per the recent New England Journal of Medicine publication titled "Zika Virus in the Americas — Yet Another Arbovirus Threat", Brazil is not alone. Authors Anthony S. Fauci, M.D., and David M. Morens, M.D., from the National Institute of Allergy and Infectious Diseases noted, "The explosive pandemic of Zika virus infection occurring throughout South America, Central America, and the Caribbean and potentially threatening the United States is the most recent of four unexpected arrivals of important arthropod-borne viral diseases in the Western Hemisphere over the past 20 years."
Samuel Broder, M.D., SVP and Head of Intrexon's Health Sector commented, "As a vector that transmits a number of serious diseases, the Aedes aegypti mosquito poses a major threat to public health and the economic welfare of nations. Brazil has been hard hit by dengue and the situation there has been aggravated by the recent introduction of Zika virus infections leading to a startling increase in the number of children being born with microcephaly." Dr. Broder continued, "Through the responsible engineering of biology, we demonstrate a new paradigm of species-specific vector control resulting in dramatic reductions of dangerous mosquitoes, without persistence or harm to the ecosystem, representing a major scientific, environmental and clinical advance."
Diseases spread by the Aedes aegypti mosquito:
About Oxitec
Oxitec is the only GM insect company in the world and a pioneer in using genetic engineering to control insect pests that spread disease and damage crops. Oxitec was founded in 2002 as a spinout from Oxford University (UK), and is now a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world's biggest problems. Oxitec's self-limiting insect control targets only the one species of pest in a way that is non-toxic and pesticide-free, providing vector control that is both effective and environmentally friendly. Follow us on Twitter at @Oxitec.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon.
Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information contact:
Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
[email protected]
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
[email protected]
Oxitec Contact:
Chris Creese, Ph.D.
Communications Manager
Tel: +44 (0) 7972 103372
[email protected]
Media Contact:
Elana Ferrari
Edelman US
Tel: +1 (312) 233-1336
Email: [email protected]
Logo - http://photos.prnewswire.com/prnh/20130919/NY83283LOGO
Logo - http://photos.prnewswire.com/prnh/20160118/323303LOGO
SOURCE Intrexon Corporation
Share this article